The US FDA have notified the Austrian biotech company Activartis that Orphan Drug Designation (ODD) has been granted for its innovative Cancer Immunotherapy AV0113. The ODD applies specifically to the use of AV0113 for the treatment of malignant glioma, a very aggressive type of brain cancer...
A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment...